Exabis Library
Welcome to the e-CCO Library!
P416: Faecal calprotectin can predict mucosal healing in patients with inflammatory bowel diseases treated with vedolizumab: a prospective single-centre study
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P416: Metabolite measurement for thiopurine therapy in inflammatory bowel disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P416: Real world data on the effectiveness and safety of vedolizumab in the treatment of Crohn's disease and ulcerative colitis: the Edinburgh experience
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P416: The impact of remission on healthcare resource utilisation and costs amongst patients with inflammatory bowel disease in France, Germany, Italy, Spain, and the United Kingdom.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P416: Use of DXA in children with Inflammatory Bowel Disease – a large single centre study
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P417 Do ACE inhibitors and angiotensin II receptor blockers improve disease outcomes in inflammatory bowel disease?
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P417: 10 years of endoscopic therapy of symptomatic Crohn’s disease stenoses: a retrospective analysis of long-term results
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM
P417: Crohn disease recurrences: Nothing new under the sun?
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P417: Frequent Early Nocebo Complaints but Maintained Clinical Efficacy, Biomarker and Therapeutic drug levels following mandatory Biosimilar Switch in Patients with Inflammatory Bowel disease: Preliminary data from a Prospective Observational Cohort Study
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P417: Long-term deep remission after adalimumab discontinuation in Crohn’s disease patients.
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P417: Non-invasive assessment of liver fibrosis by transient elastography and AST to ALT ratio in patients with Crohn's disease treated with methotrexate
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P417: Seroconversion after COVID-19 Vaccination in Inflammatory Bowel Disease Patients
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P417: Ulcerative colitis: let’s talk about extent
2016
ECCO '16 Amsterdam
Friday, 22 February 2019, 9:49 AM
P418 Filgotinib decreases molecular markers of JAK1 signal transduction in Crohn’s disease: concordance with endoscopy and histopathology
2020
ECCO'20 Vienna
Thursday, 30 January 2020, 10:12 AM
P418: Development and validation of a digital health platform (IBD NutriCare) for telenutrition in patients with Inflammatory bowel disease
2022
ECCO'22
Friday, 11 February 2022, 3:52 PM
P418: Does capsule endoscopy impact clinical management in established Crohn’s Disease?
2021
ECCO'21 Virtual
Wednesday, 2 June 2021, 4:12 PM
P418: Dose escalation of oral 5-aminosalicylic acid for ulcerative colitis with Mayo endoscopic subscore of one improves long-term prognosis: a one-year multicentre, open-label, randomized controlled trial.
2023
ECCO’23 Copenhagen
Friday, 14 July 2023, 11:05 AM
P418: Pharmacodynamic biomarkers demonstrate dose-dependent pharmacological activity of the IL-22Fc fusion protein UTR1147A in healthy volunteers in a phase 1a clinical trial
2017
ECCO '17 Barcelona
Wednesday, 20 February 2019, 10:36 AM
P418: Predictive factors of surgery in the course of Crohn’s disease
2018
ECCO '18 Vienna
Thursday, 21 February 2019, 9:14 AM
P418: Safety and efficacy of olorinab, a peripherally restricted, highly-selective, cannabinoid receptor 2 agonist in a phase 2A study in chronic abdominal pain associated with Crohn’s disease
2019
ECCO '19 Copenhagen
Friday, 22 February 2019, 9:41 AM